secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001493152-26-012085
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mira-55 shows no cannabinoid-like CNS side effects in preclinical studies; advancing toward IND for inflammatory pain
--------------------------------------------------------------------------------

- Mira-55 tested at 10, 30, and 100 mg/kg in CNS assays; no psychogenic, motor, or anxiogenic effects observed.
- No catalepsy or sedation; dose-dependent increase in time spent in open arms of Elevated Plus Maze (anxiety reduction).
- Rimonabant (positive control) showed anxiety-like behavior, validating assay sensitivity.
- Prior data demonstrated Mira-55 produced morphine-comparable analgesia in inflammatory pain model without opioid risks.
- Company plans IND submission for inflammatory pain; additional preclinical studies ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226012085/0001493152-26-012085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226012085/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-012085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer